Date: 06/30/2022

Your Name: Manisha Cole

Manuscript Title: <u>Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a pre-vaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.</u>

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | -   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article | None Abbott Laboratories   | provided the reagents for the SARS-CoV-2 IgG II assays                              |
|   | processing charges, etc.)  No time limit for this item.   |  |   |
|   |   |  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                      | x_None   |   |
| 3 | Royalties or licenses   | xNone  |   |
| 4 | Consulting fees   | x_None   |   |

| 5    | Payment or honoraria for                          | xNone                    |                 |
|------|---|--------------------------|-----------------|
|      | lectures, presentations,                          |                          |                 |
|      | speakers bureaus,                                 |                          |                 |
|      | manuscript writing or                             |                          |                 |
|      | educational events                                |                          |                 |
| 6    | Payment for expert                                | _xNone                   |                 |
|      | testimony   |                          |                 |
|      |   |                          |                 |
| 7    | Support for attending meetings and/or travel      | _xNone                   |                 |
|      | <b>5</b> ,  |                          |                 |
|      |   |                          |                 |
| 8    | Patents planned, issued or                        | xNone                    |                 |
|      | pending   |                          |                 |
|      |   |                          |                 |
| 9    | Participation on a Data                           | xNone                    |                 |
|      | Safety Monitoring Board or                        |                          |                 |
|      | Advisory Board                                    |                          |                 |
| 10   | Leadership or fiduciary role                      | x_None                   |                 |
|      | in other board, society,                          |                          |                 |
|      | committee or advocacy                             |                          |                 |
|      | group, paid or unpaid                             |                          |                 |
| 11   | Stock or stock options                            | x_None                   |                 |
|      |   |                          |                 |
| 4.2  | 5   | N                        |                 |
| 12   | Receipt of equipment,                             | x_None                   |                 |
|      | materials, drugs, medical writing, gifts or other |                          |                 |
|      | services  |                          |                 |
| 13   | Other financial or non-                           | _xNone                   |                 |
|      | financial interests                               |                          |                 |
|      |   |                          |                 |
|      |   |                          |                 |
|      |   |                          |                 |
| Dlas |   | afiat of interest in the | iallassina kass |

| Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays |
|---|
|   |
|   |

Please place an "X" next to the following statement to indicate your agreement:

\_\_x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 06/30/2022

**Your Name:** Maura C Dodge

Manuscript Title: <u>Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a pre-vaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.</u>

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None Abbott Laboratories   | provided the reagents for the SARS-CoV-2 IgG II assays                              |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | xNone  |   |
| 3 | Royalties or licenses   | xNone  |   |
| 4 | Consulting fees   | xNone  |   |

| 5  | Payment or honoraria for                        | xNone                    |                 |
|----|---|--------------------------|-----------------|
|    | lectures, presentations,                        |                          |                 |
|    | speakers bureaus,                               |                          |                 |
|    | manuscript writing or                           |                          |                 |
|    | educational events                              |                          |                 |
| 6  | Payment for expert                              | _xNone                   |                 |
|    | testimony                                       |                          |                 |
|    |   |                          |                 |
| 7  | Support for attending meetings and/or travel    | _xNone                   |                 |
|    | ,   |                          |                 |
|    |   |                          |                 |
| 8  | Patents planned, issued or                      | xNone                    |                 |
|    | pending   |                          |                 |
|    |   |                          |                 |
| 9  | Participation on a Data                         | xNone                    |                 |
|    | Safety Monitoring Board or                      |                          |                 |
|    | Advisory Board                                  |                          |                 |
| 10 | Leadership or fiduciary role                    | x_None                   |                 |
|    | in other board, society,                        |                          |                 |
|    | committee or advocacy                           |                          |                 |
|    | group, paid or unpaid                           |                          |                 |
| 11 | Stock or stock options                          | x_None                   |                 |
|    |   |                          |                 |
| 12 | Descint of agricument                           | y None                   |                 |
| 12 | Receipt of equipment, materials, drugs, medical | xNone                    |                 |
|    | writing, gifts or other                         |                          |                 |
|    | services  |                          |                 |
| 13 | Other financial or non-                         | _xNone                   |                 |
|    | financial interests                             |                          |                 |
|    |   |                          |                 |
|    |   |                          |                 |
|    |   |                          |                 |
| DI |   | afica of interest in the | iallassina hass |

| Abbott Diagnostics provide | d the reagents for the SARS-CoV-2 IgG II assays |
|----------------------------|---|
|                            |   |
|                            |   |

Please place an "X" next to the following statement to indicate your agreement:

\_\_x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date: 06/30/2022              |   |
|-------------------------------|---|
| Your Name: Elizabeth R. Duffy | · |

Manuscript Title: <u>Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a pre-vaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.</u>

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initia   | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None Abbott Laboratories   | Providing testing kits and some salary support to run the assays                    |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | _XNone   |   |
| 4 | Consulting fees   | XNone  |   |

|    |  |        | <del>_</del> |
|----|--|--------|--------------|
|    |  |        |              |
|    |  |        |              |
| 5  | Payment or honoraria for                     | _XNone |              |
|    | lectures, presentations,                     |        |              |
|    | speakers bureaus,                            |        |              |
|    | manuscript writing or                        |        |              |
|    | educational events                           |        |              |
| 6  | Payment for expert                           | _XNone |              |
|    | testimony                                    |        |              |
|    |  |        |              |
| 7  | Support for attending meetings and/or travel | _XNone |              |
|    |  |        |              |
|    |  |        |              |
| 8  | Patents planned, issued or                   | _XNone |              |
|    | pending                                      |        |              |
|    |  |        |              |
| 9  | Participation on a Data                      | _XNone |              |
|    | Safety Monitoring Board or                   |        |              |
|    | Advisory Board                               |        |              |
| 10 | Leadership or fiduciary role                 | _XNone |              |
|    | in other board, society,                     |        |              |
|    | committee or advocacy                        |        |              |
|    | group, paid or unpaid                        |        |              |
| 11 | Stock or stock options                       | XNone  |              |
|    |  |        |              |
|    |  |        |              |
| 12 | Receipt of equipment,                        | _XNone |              |
|    | materials, drugs, medical                    |        |              |
|    | writing, gifts or other services             |        |              |
| 13 | Other financial or non-                      | _XNone |              |
|    | financial interests                          |        |              |
|    |  |        |              |
|    |  |        |              |
|    |  |        |              |

Abbott laboratories provided testing kits and some salary support in order to measure the different antibody targets for SARS-CoV-2.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date: 06/30/20 | 22 |
|----------------|----|
|----------------|----|

| Your Name: J | ordyn Osterland |
|--------------|-----------------|
|--------------|-----------------|

Manuscript Title: <u>Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a pre-vaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.</u>

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None Abbott Laboratories  | provided the reagents for the SARS-CoV-2 IgG II assays                              |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses   | Time frame: pastXNoneXNone  | 36 months   |
| 4 | Consulting fees   | XNone   |   |

| 5    | Payment or honoraria for  | XNone  |  |
|------|---|--------|--|
|      | lectures, presentations,  |        |  |
|      | speakers bureaus,   |        |  |
|      | manuscript writing or   |        |  |
|      | educational events  |        |  |
| 6    | Payment for expert  | XNone  |  |
|      | testimony   |        |  |
|      | -   |        |  |
| 7    | Support for attending meetings and/or travel                          | XNone  |  |
|      |   |        |  |
|      |   |        |  |
| 8    | Patents planned, issued or  | XNone  |  |
|      | pending   |        |  |
|      |   |        |  |
| 9    | Participation on a Data   | X_None |  |
|      | Safety Monitoring Board or  |        |  |
|      | Advisory Board  |        |  |
| 10   | Leadership or fiduciary role  | XNone  |  |
|      | in other board, society,  |        |  |
|      | committee or advocacy group, paid or unpaid                           |        |  |
| 11   | Stock or stock options  | XNone  |  |
|      |   |        |  |
|      |   |        |  |
| 12   | Receipt of equipment,   | XNone  |  |
|      | materials, drugs, medical   |        |  |
|      | writing, gifts or other services                                      |        |  |
| 13   |   | X None |  |
| 13   | Other financial or non-<br>financial interests                        |        |  |
|      | imanciai interests  |        |  |
|      |   |        |  |
| Plea | Please summarize the above conflict of interest in the following box: |        |  |

| Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays |  |  |
|---|--|--|
|   |  |  |
|   |  |  |

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 06/30/2022

Your Name: Susan H. Gawel

Manuscript Title: <u>Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a pre-vaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.</u>

Manuscript number (if known): <u>JLPM-22-19-CL</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone Abbott Laboratories   | provided the reagents for the SARS-CoV-2 IgG II assays                              |
| 3 | Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses   | None None None  | 36 months   |
| 4 | Consulting fees   | None  |   |

| _  |                              |      |  |
|----|------------------------------|------|--|
| 5  | Payment or honoraria for     | None |  |
|    | lectures, presentations,     |      |  |
|    | speakers bureaus,            |      |  |
|    | manuscript writing or        |      |  |
|    | educational events           |      |  |
| 6  | Payment for expert           | None |  |
|    | testimony                    |      |  |
|    | •                            |      |  |
| 7  | Support for attending        | None |  |
|    | meetings and/or travel       |      |  |
|    | g,                           |      |  |
|    |                              |      |  |
|    |                              |      |  |
|    |                              |      |  |
| 8  | Patents planned, issued or   | None |  |
|    | pending                      |      |  |
|    |                              |      |  |
| 9  | Participation on a Data      | None |  |
|    | Safety Monitoring Board or   |      |  |
|    | Advisory Board               |      |  |
| 10 | Leadership or fiduciary role | None |  |
|    | in other board, society,     |      |  |
|    | committee or advocacy        |      |  |
|    | group, paid or unpaid        |      |  |
| 11 | Stock or stock options       | X    |  |
|    | ·                            |      |  |
|    |                              |      |  |
| 12 | Receipt of equipment,        | None |  |
|    | materials, drugs, medical    |      |  |
|    | writing, gifts or other      |      |  |
|    | services                     |      |  |
| 13 | Other financial or non-      | X    |  |
| 13 | financial interests          | ^    |  |
|    | iniancial interests          |      |  |
|    |                              |      |  |
|    |                              |      |  |

| Susan H. Gawel is an employee of Abbott Labs and Abbott Diagnostics provided the reagents for the SARS-CoV-2 Ig |
|---|
| Il assays.  |

Please place an "X" next to the following statement to indicate your agreement:

\_x\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 06/30/2022 Your Name: <u>Lei Ye</u>

Manuscript Title: <u>Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a prevaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.</u>

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                             | None   |   |
|   | manuscript (e.g., funding,                              | Abbott Laboratories  | provided the reagents for the SARS-CoV-2 IgG II assays                              |
|   | provision of study materials,                           |  |   |
|   | medical writing, article                                |  |   |
|   | processing charges, etc.)  No time limit for this item. |  |   |
|   | No time mint for this item.                             |  |   |
|   |   |  |   |
|   |   | Time frame: post   | 26 months   |
| 2 | Grants or contracts from                                | Time frame: past X None  | 36 MONUS  |
| 2 | any entity (if not indicated                            | XNone  |   |
|   | in item #1 above).                                      |  |   |
| 3 | Royalties or licenses                                   | X None   |   |
|   | no farcies of moenses                                   |  |   |
|   |   |  |   |
| 4 | Consulting fees   | XNone  |   |
|   | <u>-</u>  |  |   |
|   |   |  |   |
| 5 |   | XNone  |   |

|    |                              | _      |  |
|----|------------------------------|--------|--|
|    | Payment or honoraria for     |        |  |
|    | lectures, presentations,     |        |  |
|    | speakers bureaus,            |        |  |
|    | manuscript writing or        |        |  |
|    | educational events           |        |  |
| 6  | Payment for expert           | X None |  |
|    | testimony                    |        |  |
|    | ,                            |        |  |
| 7  | Support for attending        | X None |  |
| ′  | meetings and/or travel       | XNone  |  |
|    | meetings and/or traver       |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |
| 8  | Patents planned, issued or   | XNone  |  |
|    | pending                      |        |  |
|    |                              |        |  |
| 9  | Participation on a Data      | XNone  |  |
|    | Safety Monitoring Board or   |        |  |
|    | Advisory Board               |        |  |
| 10 | Leadership or fiduciary role | X None |  |
|    | in other board, society,     |        |  |
|    | committee or advocacy        |        |  |
|    | group, paid or unpaid        |        |  |
| 11 | Stock or stock options       | X None |  |
|    | COUNTY SECON OPTIONS         |        |  |
|    |                              |        |  |
| 12 | Receipt of equipment,        | X None |  |
| 12 | materials, drugs, medical    |        |  |
|    | writing, gifts or other      |        |  |
|    | services                     |        |  |
| 12 | Other financial or non-      | V None |  |
| 13 |                              | XNone  |  |
|    | financial interests          |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |

| Lei Ye is an employee of Abbott Labs and Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays. |
|---|
|   |
|   |

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 06/30/2022

**Your Name:** Kyle de la Cena

Manuscript Title: <u>Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a prevaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.</u>

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All according to the property  |   | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | None Abbott Laboratories  | provided the reagents for the SARS-CoV-2 IgG II assays                              |
|   | medical writing, article processing charges, etc.)  No time limit for this item.     |   |   |
|   | No time illinit for tims item.   |   |   |
|   |  |   |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from   | XNone   |   |
|   | any entity (if not indicated in item #1 above).                                      |   |   |
| 3 | Royalties or licenses  | XNone   |   |
|   |  |   |   |
| 4 | Consulting fees  | XNone   |   |
|   |  |   |   |
|   |  |   |   |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events                                     | _XNone |  |  |
|----|--|--------|--|--|
| 6  | Payment for expert testimony   | X_None |  |  |
| 7  | Support for attending meetings and/or travel   | XNone  |  |  |
| 8  | Patents planned, issued or pending   | XNone  |  |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | _XNone |  |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  | XNone  |  |  |
| 11 | Stock or stock options   | XNone  |  |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services  | XNone  |  |  |
| 13 | Other financial or non-<br>financial interests   | X_None |  |  |
|    | Please summarize the above conflict of interest in the following box:  Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays |        |  |  |
|    |  |        |  |  |

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 06/30/2022

**Your Name:** Elizabeth J. Ragan

Manuscript Title: Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a pre-

vaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|  | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution)  |
|--|---|--|
| All according to the property                            |   | planning of the work   |
| manuscript (e.g., funding, provision of study materials, | Abbott Laboratories   | provided the reagents for the SARS-CoV-2 IgG II assays   |
| medical writing, article processing charges, etc.)       |   |  |
| No time limit for this item.                             |   |  |
|  |   |  |
|  | Time frame: nast  | 36 months  |
| Grants or contracts from                                 | XNone   | 30 months  |
| any entity (if not indicated in item #1 above).          |   |  |
| Royalties or licenses                                    | _XNone  |  |
|  |   |  |
| Consulting fees  | XNone   |  |
|  |   |  |
|  | provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses | whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Time frame: past  Abbott Laboratories  Time frame: past  X_None  Ay None  Time frame: past  X_None  X_None  Royalties or licenses  X_None |

| 5  | Payment or honoraria for                     | XNone  |  |
|----|--|--------|--|
|    | lectures, presentations,                     |        |  |
|    | speakers bureaus,                            |        |  |
|    | manuscript writing or                        |        |  |
|    | educational events                           |        |  |
| 6  | Payment for expert                           | XNone  |  |
|    | testimony                                    |        |  |
|    |  |        |  |
| 7  | Support for attending meetings and/or travel | XNone  |  |
|    | <i>5</i> ,                                   |        |  |
|    |  |        |  |
| 8  | Patents planned, issued or                   | XNone  |  |
|    | pending                                      |        |  |
|    |  |        |  |
| 9  | Participation on a Data                      | _XNone |  |
|    | Safety Monitoring Board or                   |        |  |
|    | Advisory Board                               |        |  |
| 10 | Leadership or fiduciary role                 | XNone  |  |
|    | in other board, society,                     |        |  |
|    | committee or advocacy                        |        |  |
|    | group, paid or unpaid                        |        |  |
| 11 | Stock or stock options                       | _XNone |  |
|    |  |        |  |
|    |  |        |  |
| 12 | Receipt of equipment,                        | _XNone |  |
|    | materials, drugs, medical                    |        |  |
|    | writing, gifts or other                      |        |  |
|    | services                                     |        |  |
| 13 | Other financial or non-                      | XNone  |  |
|    | financial interests                          |        |  |
|    |  |        |  |
|    |  |        |  |
|    |  |        |  |

| Abbott Diagnostics provided the reagents for the SARS-CoV-2 IgG II assays |  |
|---|--|
|   |  |
|   |  |

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

**ICMJE DISCLOSURE FORM** 

Date: 06/30/2022

| Your Name: | Sarah Weber |  |  |
|------------|-------------|--|--|
|            |             |  |  |

Manuscript Title: <u>Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a prevaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.</u>

Manuscript number (if known): <u>JLPM-22-19-CL</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding, provision of study materials, medical writing, article | Abbott Laboratories  | provided the reagents for the SARS-CoV-2 IgG II assays                              |
|   | processing charges, etc.)   |  |   |
|   | No time limit for this item.  |  |   |
|   |   |  |   |
|   |   |  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from  | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).  |  |   |
| 3 | Royalties or licenses   | XNone  |   |
|   |   |  |   |
|   |   |  |   |
| 4 | Consulting fees   | XNone  |   |
|   |   |  |   |
| _ |   | V N  |   |
| 5 | Payment or honoraria for  | XNone  |   |
|   | lectures, presentations,  |  |   |

|    | speakers bureaus,<br>manuscript writing or<br>educational events                                  |             |   |
|----|---|-------------|---|
| 6  | Payment for expert testimony  | XNone       |   |
| 7  | Support for attending meetings and/or travel  | XNone       |   |
| 8  | Patents planned, issued or pending  | XNone       |   |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                           | XNone       |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone       |   |
| 11 | Stock or stock options  | XNone       |   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services         | XNone       |   |
| 13 | Other financial or non-<br>financial interests  | XNone       |   |
|    | ase summarize the above co  |             |   |
|    | nse place an "X" next to the<br>_ I certify that I have answe<br>form.                            | -           | licate your agreement:  eve not altered the wording of any of the questions on this |
|    |   | ICMJE DISCL | OSURE FORM  |
|    | e <u>: 06/30/2022</u><br>r Name: <u>Elissa Perkins</u>  |             |   |

Manuscript Title: Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a prevaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None Abbott Laboratories   | provided the reagents for the SARS-CoV-2 IgG II assays                              |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,   | XNone  |   |

|    | manuscript writing or        |        |  |
|----|------------------------------|--------|--|
|    | educational events           |        |  |
| 6  | Payment for expert           | XNone  |  |
|    | testimony                    |        |  |
|    | •                            |        |  |
| 7  | Support for attending        | X None |  |
| •  | meetings and/or travel       |        |  |
|    | meetings and, or traver      |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |
| 8  | Patents planned, issued or   | XNone  |  |
|    | pending                      |        |  |
|    |                              |        |  |
| 9  | Participation on a Data      | XNone  |  |
|    | Safety Monitoring Board or   |        |  |
|    | Advisory Board               |        |  |
| 10 | Leadership or fiduciary role | XNone  |  |
|    | in other board, society,     |        |  |
|    | committee or advocacy        |        |  |
|    | group, paid or unpaid        |        |  |
| 11 | Stock or stock options       | XNone  |  |
|    |                              |        |  |
|    |                              |        |  |
| 12 | Receipt of equipment,        | XNone  |  |
|    | materials, drugs, medical    |        |  |
|    | writing, gifts or other      |        |  |
|    | services                     |        |  |
| 13 | Other financial or non-      | XNone  |  |
|    | financial interests          |        |  |
|    |                              |        |  |
|    | ase summarize the above co   |        |  |
|    |                              |        |  |

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### **ICMJE DISCLOSURE FORM**

Date: 06/30/2022

Your Name: Karen Jacobson

Manuscript Title: Comparison of SARS-CoV-2 anti-Spike IgG and anti-Nucleoprotein IgG seroprevalence amongst a prevaccine cohort of healthcare workers at an academic medical center in Boston, Massachusetts.

Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None Abbott Laboratories   | provided the reagents for the SARS-CoV-2 IgG II assays                              |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | XNone  |   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,   | XNone  |   |

|      | manuscript writing or   |                            |   |
|------|---|----------------------------|---|
|      | manuscript writing or educational events                                |                            |   |
| 6    | Payment for expert  | X None                     |   |
|      | testimony   |                            |   |
|      | ·   |                            |   |
| 7    | Support for attending meetings and/or travel                            | XNone                      |   |
|      |   |                            |   |
| 8    | Patents planned, issued or pending                                      | XNone                      |   |
| 9    | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board | XNone                      |   |
| 10   | Leadership or fiduciary role  | X None                     |   |
| 10   | in other board, society,  | XNone                      |   |
|      | committee or advocacy   |                            |   |
| 11   | group, paid or unpaid   | V Nava                     |   |
| 11   | Stock or stock options  | XNone                      |   |
|      |   |                            |   |
| 12   | Receipt of equipment,   | X None                     |   |
|      | materials, drugs, medical   |                            |   |
|      | writing, gifts or other   |                            |   |
| 42   | services  | V None                     |   |
| 13   | Other financial or non-<br>financial interests                          | XNone                      |   |
|      | illialiciai liiterests  |                            |   |
|      | se summarize the above co   |                            |   |
|      | se place an "X" next to the I certify that I have answe                 | -                          | licate your agreement:  Ive not altered the wording of any of the questions on this |
|      |   | ICMJE DISCL                | OSURE FORM  |
| Date | e: 06/30/2022   |                            |   |
|      | <mark>r Name: Yachana Katari</mark>                                     | a                          |   |
| Mar  | nuscript Title: Comparison o  | f SARS-CoV-2 anti-Spike Ig | G and anti-Nucleoprotein IgG seroprevalence amongst a pre                           |
| vaco | ine cohort of healthcare wo   | orkers at an academic med  | ical center in Boston, Massachusetts.   |

### Manuscript number (if known): JLPM-22-19-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | X_None  | Abbott Diagnostics to institution BMC Internal Grant funding  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | Time frame: pastNone  | 36 months See Above   |
| 3 | Royalties or licenses   | xNone   |   |
| 4 | Consulting fees   | x_None  |   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  | _xNone  |   |
| 6 |   | x_None  |   |

|    | Payment for expert                                    |        |                                     |
|----|---|--------|-------------------------------------|
|    | testimony   |        |                                     |
| 7  | Support for attending meetings and/or travel          | xNone  |                                     |
|    |   |        |                                     |
|    |   |        |                                     |
| 8  | Patents planned, issued or                            | x_None |                                     |
|    | pending   |        |                                     |
| _  |   |        |                                     |
| 9  | Participation on a Data                               | xNone  |                                     |
|    | Safety Monitoring Board or<br>Advisory Board          |        |                                     |
| 10 | •   | Nana   |                                     |
| 10 | Leadership or fiduciary role in other board, society, | None   |                                     |
|    | committee or advocacy                                 |        |                                     |
|    | group, paid or unpaid                                 |        |                                     |
| 11 | Stock or stock options                                | xNone  |                                     |
|    |   |        |                                     |
|    |   |        |                                     |
| 12 | Receipt of equipment,                                 | None   | Reagent Kits form Abbott Diagnostic |
|    | materials, drugs, medical                             |        |                                     |
|    | writing, gifts or other                               |        |                                     |
| 13 | services Other financial or non-                      | x None |                                     |
| 13 | financial interests                                   |        |                                     |
|    | manara meereses                                       |        |                                     |
|    |   |        |                                     |
|    |   |        |                                     |
| _  |   |        |                                     |

| Funding for this study, partly from Abbott Diagnostics that provided free Reagent Kits. |
|---|
|   |
|   |

Please place an "X" next to the following statement to indicate your agreement:

\_\_x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.